Humana Inc. (NYSE:HUM) Shares Sold by Manning & Napier Advisors LLC

Manning & Napier Advisors LLC reduced its stake in Humana Inc. (NYSE:HUM) by 97.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,957 shares of the insurance provider’s stock after selling 237,735 shares during the period. Manning & Napier Advisors LLC’s holdings in Humana were worth $1,765,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in HUM. Creative Financial Designs Inc. ADV lifted its stake in shares of Humana by 244.0% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after acquiring an additional 61 shares during the period. Atwood & Palmer Inc. acquired a new stake in Humana during the third quarter valued at approximately $29,000. Ashton Thomas Securities LLC acquired a new stake in Humana during the third quarter valued at approximately $31,000. Your Advocates Ltd. LLP lifted its stake in Humana by 81.8% during the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 45 shares during the last quarter. Finally, LRI Investments LLC lifted its stake in Humana by 1,021.4% during the third quarter. LRI Investments LLC now owns 157 shares of the insurance provider’s stock valued at $50,000 after purchasing an additional 143 shares during the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the transaction, the insider now owns 8,181 shares of the company’s stock, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.32% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on the stock. KeyCorp assumed coverage on shares of Humana in a research note on Friday, October 11th. They set a “sector weight” rating for the company. Truist Financial boosted their price target on shares of Humana from $260.00 to $290.00 and gave the company a “hold” rating in a report on Monday, January 6th. Wells Fargo & Company cut their price target on shares of Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. UBS Group cut their price target on shares of Humana from $380.00 to $250.00 and set a “neutral” rating on the stock in a report on Friday, October 4th. Finally, Jefferies Financial Group lowered shares of Humana from a “buy” rating to a “hold” rating and cut their price target for the company from $519.00 to $253.00 in a report on Monday, October 7th. Nineteen investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $297.68.

Humana Price Performance

Shares of Humana stock opened at $296.88 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The firm has a fifty day moving average price of $275.44 and a two-hundred day moving average price of $303.07. The company has a market cap of $35.75 billion, a PE ratio of 26.30, a price-to-earnings-growth ratio of 2.15 and a beta of 0.55.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, beating the consensus estimate of $3.48 by $0.68. The firm had revenue of $29.30 billion during the quarter, compared to analysts’ expectations of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. Analysts expect that Humana Inc. will post 16.11 EPS for the current year.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.